NeuroSense Therapeutics Ltd. Ordinary Shares
NRSN
Closed
$0.71
Closed
-(-)
At close
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply
About
Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company, which engages n the discovery and development of targeted therapeutics for neurodegenerative diseases. The firm is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The firm's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
Key stats
Open
$0.70
Volume
54.82K
Market cap
$25.05M
Prev. close
$0.71
Impl / hst vl
-
Open interest
$0.00
$0.68
Day’s Range
$0.73
$0.63
52W Range
$1.10
Valuation
11
Valuation score
Strongly Overvalued
P/E
-
P/S
-
P/B
-
Current ratio
-
Debt / Equity
-
ROE
-
Gross margin
-
Income growth
136.25%
FCF growth
-8.26
Analysts estimates
Consensus rating
Buy
The average rating from top 6 analysts indicates that stock is expected to perform in line with the market
Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$6.63
The top 5 analysts forecasts that 12-month price may increase by 833.80%, with a low of $3.03 and a high of $9.45
$3.03
Low
$6.63
Avg
$9.45
High
Current price
Earnings
Q4 ‘25 revenue
$0.00
Q4 ‘25 net income
-$11.13M
Revenue
Net income
Previous EPS
-Estimate EPS
-$0.16
Actual EPS
Estimate EPS
Explore the Healthcare sector
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply